Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efzofitimod - aTyr Pharma

Next Previous
Drug Profile

Efzofitimod - aTyr Pharma

Alternative Names: ATY 1923; ATYR-1923; iMod.Fc; KRP-R120; Stalaris

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator aTyr Pharma
  • Developer aTyr Pharma; Foundation for Sarcoidosis Research; Kyorin Pharmaceutical
  • Class Anti-inflammatories; Antifibrotics; Antirheumatics; Antivirals; Immunoglobulin Fc fragments; Proteins; Recombinant fusion proteins
  • Mechanism of Action Neuropilin-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pulmonary sarcoidosis
  • Phase II COVID-19 pneumonia; Interstitial lung diseases
  • Preclinical Rheumatoid arthritis
  • No development reported Pulmonary fibrosis

Most Recent Events

  • 14 Mar 2024 aTyr Pharma announces intention to file Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis
  • 14 Mar 2024 aTyr Pharma initiates an Individual Patient Expanded Access Program (EAP) for Pulmonary sarcoidosis (In adults, In the elderly, Treatment-experienced) (IV, Infusion)
  • 21 Feb 2024 aTyr Pharma plans Individual Patient Expanded Access Program (EAP) for Pulmonary sarcoidosis (In adults, In the elderly, Treatment-experienced) (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top